Search Results for "Roy Poses"
Podcast: Doctors who blog
This podcast is about physicians who blog …
Why they do it, what they’ve taken away from the experience, and what they see as the role blogging plays in the medical information landscape.1
Lowering the bar on Alzheimer’s drugs: STAT op-ed takes industry-friendly line, without disclosing author’s pharma ties
A recent op-ed published Monday in STAT insists that proposed FDA guidance for Alzheimer’s drug development is “good news” that “removes unnecessary barriers” to bring new medications to market. If the guidance is finalized, pharmaceutical companies would no longer have to prove that their drugs impact the endpoints of “cognition and function” when tested on […]1
Conflicts of interest in medicine: pervasive, worrisome, and detrimental to healthcare
The well-respected medical journal, JAMA Internal Medicine, has published a special collection of articles highlighting blatant conflicts of interest between healthcare and industry. It’s a topic we’ve covered hundreds of times dating back to the spring of 2005 and we’re glad to see it getting special attention. Before launching into the JAMA articles I wanted […]
Black box warnings for ‘lifesaving’ hepatitis C drugs highlight systematic misinformation
You may have seen the news a few weeks ago that the FDA is now requiring a “black box warning” on drug labels for certain antiviral hepatitis C medications known as direct-acting antivirals. As Roy Poses, MD, noted on the blog Health Care Renewal, the drugs have been reported to reactivate dormant hepatitis B infections, a […]4
What if we had an election and counted only half the ballots? When you’re burying research you’re also likely burying patients
Alan Cassels is a pharmaceutical policy researcher at the University of Victoria. He’s also one of our reviewers and a regular contributor to the blog. As a group that aims to monitor and hopefully improve health news reporting, we sometimes notice what doesn’t make the news. Clearly the sexiest, most headline-generating and most tweetable topics come from […]4
Responding to parts 2-3 of New England Journal of Medicine’s series on pharma-MD relations
Dr. Susan Molchan responds to the second and third pieces of a series by New England Journal of Medicine national correspondent Dr. Lisa Rosenbaum: Understanding Bias –The Case for Careful Study, and Beyond Moral Outrage –Weighing the Trade-Offs of COI Regulation. Last week, she was one of the first critics of part one of the […]1/16/2015
The Friday file of things I wish I’d addressed earlier
Better late than never, here’s some interesting catch-up reading. An Analysis piece in The BMJ by Ronald Koretz, Kenny Lin, John Ioannidis and Jeanne Lenzer, “Is widespread screening for hepatitis C justified?“ The key messages, as summarized in The BMJ: The CDC and other major organisations are recommending birth cohort population screening for hepatitis C […]9/3/2014
After Barcelona buzz wears off, questions remain about new heart drugs
From the big European Society of Cardiology annual meeting in Barcelona come these headlines: Cholesterol Drug Halves Heart Attack and Stroke in Early Test Magic Cholesterol Pill Halves Heart Attack Risk The first was from the New York Times, picking up a Reuters story. Seeing that, Yale’s Dr. Harlan Krumholz tweeted: “This @nytimes headline sends […]1/3/2013
Catching up on Conflict of Interest news. Please make it stop.
A little end-of-the-year clean up of desk clutter never hurts. Well, yes it does when you see the accumulation of health care confilct of interest stories that have piled up recently. I had started this cleanup at the end of 2012 but am just now getting around to publishing it. Doctors with links to drug […]2 11/1/2012
Reporting on the Medtronic mess – a recipe for home cooking in Twin Cities?
One of the most thorough examinations of the Senate Finance Committee report on Medtronic’s research and marketing of its spinal surgery product, Infuse, was delivered by Roy Poses on his Health Care Renewal blog: “Marketers’ Systemic Influence over Ostensibly Scholarly, Peer-Reviewed Publications: the Medtronic Infuse BMP-2 Example.” His powerful concluding suggestion: “Going forward, we must […]12/22/2011
Unwrapping early presents, wrapping up ’11 Health Wonk Review series
A sleigh led by a dog. Hey, the red-nosed reindeer had nothing on this mutt. Like Rudolph’s maiden voyage with the fat man, this is the Watchdog’s first time hosting the Wonk Review. So buckle up for a wild ride. Man, there’s a lot in Santa’s bag: unbundling the bundle in the jungle, […]2/17/2011
Pleased to get top billing on this week's Health Wonk Review
The Colorado Long Term Care Insider blog hosts this week’s edition of the Health Wonk Review, and I’m honored to have them give top billing to my newspaper editorial calling for balance in cancer screening messages. But the new roundup also includes entries from: Maggie Mahar Austin Frakt at the Incidental Economist Jason Shafrain […]
Newsweek story on Zika vaccine to zap brain cancer is fascinating–but needed more caution about mouse research
The story does express some limitations of the study findings, which we appreciate.
GLIOBLASTOMA: ZIKA VIRUS COULD DESTROY BRAIN CANCER THAT KILLED JOHN MCCAIN
Court records show how a medical device ‘seeding trial’ disguised marketing as science
As a new line of hip implants was about to be launched in 2000, a stunning email went out from the manufacturer’s marketing department. It described a “clinical research strategy” to pay orthopedic surgeons $400 for each patient they enrolled in a company-sponsored trial. Ostensibly the trial was intended to measure how often liners of […]
Nonsurgical treatment for infants with ear deformities: Release doesn’t disclose conflicts of interest
A discussion on deformed versus malformed ears would have added some much needed clarity to the release.